Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact
Executive Summary
In theory, reviewing generic applications faster should speed competition; in practice, FDA's new policy likely won't make too much difference.
You may also be interested in...
Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
Company says that while FDA has focused on expediting approval of third and fourth generics, it has not done so for first generics and complex products.
Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
Company says that while FDA has focused on expediting approval of third and fourth generics, it has not done so for first generics and complex products.
Generic Drug Market Has Gaps, FDA Tells Firms In Solicitation For ANDAs
US agency unveils plans to speed reviews of generic applications in areas with limited competition and offers a list of potential targets, but threat to brands may be limited.